ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
R&D Expenses : R&D expenses increased to $141.8 million in 2023, up from $98.4 million in 2022. Net Loss : GAAP net loss widened to $160.8 million for 2023, or ($3.74) per share, from $123.5 million in 2022. Funding : ALXO raised approximately $63.2 million in an oversubscribed public offering to extend its cash runway into early 2026. Clinical Milestones : Positive interim results from the ASPEN-06 Phase 2 trial and multiple upcoming data readouts in 2024. Warning! GuruFocus has detected 4 Warning Signs with ALXO. On March 7, 2024, ALX Oncology Holdings Inc ( NASDAQ:ALXO ) released its 8-K filing , detailing the financial results for the fourth quarter and the full year ended December 31, 2023, alongside a corporate update. The clinical-stage immuno-oncology company, known for its development of therapies that block the CD47 immune checkpoint pathway, has reported a year of significant progress, particularly with its lead product candidate, evorpacept. Company Overview a
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingGlobeNewswire
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
ALXO
Earnings
- 11/13/23 - Miss
ALXO
Sec Filings
- 4/23/24 - Form ARS
- 4/22/24 - Form DEF
- 4/18/24 - Form 4
- ALXO's page on the SEC website